Moving an object from one location to another—picking and placing—is an ideal application for industrial robots due to the robots’ repeatability, throughput and favorable return on investment. It is ...

As a massive winter storm barrels across the U.S., power grid operators are taking extraordinary steps to keep the lights on and avoid rolling blackouts. The storm, stretching more than 2,300 miles, ...

Automatic mesh generation, recognized as the “Holy Grail” of Computational Fluid Dynamics (CFD), was highlighted as a critical objective in the NASA CFD Vision 2030 study. Adaptive Cartesian grid ...

FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...

An early grid battery was installed in the Atacama Desert in Chile 15 years ago. Now, as prices have tumbled, they are increasingly being used around the world. Andes Solar IV, one of the largest ...

Massive data centers are pushing energy demand higher. Some people claim that AI will be a net benefit for the grid. The rising popularity of AI is driving an increase in electricity demand so ...

Championship leader Alex Palou wins pole position for the IndyCar Series race at WeatherTech Raceway at Laguna Seca, his fifth pole of the season. Pato O'Ward — second in the points but not all that ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...

When the lights went out across the Iberian Peninsula in April, everything ground to a halt. Scores of people were trapped in Madrid’s underground metro system. Hospitals in Lisbon had to switch to ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 units, at a price of ...